Log in to email corresponding author
|
Cite this article:
Anthony Kodzo-Grey Venyo, David Herring, Harold Greenwood, Douglas John Lindsay Maloney. The expression of Beta Human Chorionic Gonadotrophin (beta-HCG) in human urothelial carcinoma. The Pan African Medical Journal. 2010;7:20 Key words: Urothelial, carcinoma, beta-HCG, Immunohistochemistry, Bladder Cancer Permanent link: http://www.panafrican-med-journal.com/content/article/7/20/full Received: 23/10/2010 - Accepted: 02/12/2010 - Published: 16/12/2010 © Anthony Kodzo-Grey Venyo et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
The expression of Beta Human Chorionic Gonadotrophin (β-HCG) in human urothelial carcinoma
Anthony Kodzo-Grey Venyo1,&, David Herring 2, Harold Greenwood3, Douglas John Lindsay Maloney4
1North Manchester General Hospital, Department of Urology Delaunays Road Crumpsall Manchester M85RB, United Kingdom, 2University Hospital of North Durham, Department of Surgery North Road Durham City DH1 5TW, United Kingdom, 3University Hospital of North Durham Department of Pathology North Road Durham City DH1 5TW, United Kingdom, 4Airedale General Hospital Department of Pathology Skipton Road Steeton Keigley West Yorkshire BD20 6TD, United Kingdom
&Corresponding author
Anthony Kodzo-Grey Venyo,North Manchester General Hospital, Department of Urology, Delaunays Road, Crumpsall, Manchester M8 5RB, Telephone 44 (0) 161 720 2468 / 44 (0) 161 720 2388, Fax: 44 (0) 161 720 2228, United Kingdom
Studies regarding the immuno-histological expression and relevance of Beta-Human Chorionic Gonadotrophin (β-HCG) in urothelial carcinoma are few. There is also no clear cut way of predicting exactly which superficial urothelial carcinomas would subsequently recur or progress and which muscle-invasive urothelial tumours would progress. The objective of the study was to study the immunohistological expression of β-HCG in urothelial carcinoma with regards to grade, category and outcome following treatment.
The expression of β-HCG in urothelial carcinomas of 86 patients was studied with regards to grade, stage and outcome using an immunohistological (ABC) method and formalin fixed/paraffin embedded tumours.
Of the 86 tumours (55 superficial and 31 muscle-invasive) studied 45, 16 and 26 were graded as G1, G2, and G3 respectively. Thirteen of the 55 superficial tumours were positively stained for β-HCG and 42 negatively stained. Twenty of the 31 muscle-invasive tumours studied were positively stained for β-HCG and 11 were negative. Of the 13 β-HCG positive superficial tumours only one did not recur at follow up and 12 subsequently recurred, of the 42 β-HCG negative superficial tumours 19 did not recur and 23 recurred. Only one of twenty patients with β-HCG positive muscle-invasive tumours survived; 6 of 11 patients with β-HCG negative muscle-invasive tumours survived. The results indicate that positive staining of the tumours was more commonly associated with tumours of higher grade, higher stage and inferior outcome.
The Immunohistological expression of β-HCG would likely predict superficial tumours that would recur and muscle-invasive tumours with inferior outcome.
